Waters CH[au] - Search Results

Year	Number of Results
1947	1
1952	1
1957	1
1959	1
1960	1
1980	1
1990	1
1991	1
1992	3
1993	3
1994	4
1995	2
1996	2
1997	3
1998	3
1999	2
2000	1
2001	5
2002	3
2003	1
2004	2
2009	2
2010	1
2013	3
2014	3
2015	1
2016	1
2017	2
2020	3
2021	2
2022	1
2023	1
2024	0

1

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE. Espay AJ, et al. Among authors: waters ch. Neurol Clin Pract. 2017 Feb;7(1):86-93. doi: 10.1212/CPJ.0000000000000316. Neurol Clin Pract. 2017. PMID: 28243505 Free PMC article. Review.

2

The Clinical Development of Levodopa Inhalation Powder.

Hauser RA, LeWitt PA, Waters CH, Grosset DG, Blank B. Hauser RA, et al. Among authors: waters ch. Clin Neuropharmacol. 2023 Mar-Apr 01;46(2):66-78. doi: 10.1097/WNF.0000000000000540. Epub 2023 Jan 29. Clin Neuropharmacol. 2023. PMID: 36715241 Free PMC article.

3

Essential Tremor.

Lambert D, Waters CH. Lambert D, et al. Among authors: waters ch. Curr Treat Options Neurol. 1999 Mar;1(1):6-13. doi: 10.1007/s11940-999-0027-3. Curr Treat Options Neurol. 1999. PMID: 11096690

4

Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.

Wright BA, Waters CH. Wright BA, et al. Among authors: waters ch. Expert Rev Neurother. 2013 Jun;13(6):719-29. doi: 10.1586/ern.13.47. Expert Rev Neurother. 2013. PMID: 23739008 Review.

5

Current strategies in the treatment of Parkinson's disease and a personalized approach to management.

Diaz NL, Waters CH. Diaz NL, et al. Among authors: waters ch. Expert Rev Neurother. 2009 Dec;9(12):1781-9. doi: 10.1586/ern.09.117. Expert Rev Neurother. 2009. PMID: 19951137 Review.

6

Comparative tolerability of the newer generation antiparkinsonian agents.

Lambert D, Waters CH. Lambert D, et al. Among authors: waters ch. Drugs Aging. 2000 Jan;16(1):55-65. doi: 10.2165/00002512-200016010-00005. Drugs Aging. 2000. PMID: 10733264 Review.

7

Managing the late complications of Parkinson's disease.

Waters CH. Waters CH. Neurology. 1997 Jul;49(1 Suppl 1):S49-57. doi: 10.1212/wnl.49.1_suppl_1.s49. Neurology. 1997. PMID: 9222274 Review.

8

Treatment of advanced stage patients with Parkinson's disease.

Waters CH. Waters CH. Parkinsonism Relat Disord. 2002 Oct;9(1):15-21. doi: 10.1016/s1353-8020(02)00040-8. Parkinsonism Relat Disord. 2002. PMID: 12217618 Review.

9

Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson's Disease.

Yu E, Rudakou U, Krohn L, Mufti K, Ruskey JA, Asayesh F, Estiar MA, Spiegelman D, Surface M, Fahn S, Waters CH, Greenbaum L, Espay AJ, Dauvilliers Y, Dupré N, Rouleau GA, Hassin-Baer S, Fon EA, Alcalay RN, Gan-Or Z. Yu E, et al. Among authors: waters ch. Mov Disord. 2021 Jan;36(1):178-187. doi: 10.1002/mds.28299. Epub 2020 Sep 24. Mov Disord. 2021. PMID: 32970363

10

Advances in managing Parkinson's disease.

Waters CH. Waters CH. Hosp Pract (1995). 2001 Jun 15;36(6):27-32, 41. doi: 10.3810/hp.2001.06.240. Hosp Pract (1995). 2001. PMID: 11419534

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

60 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year